

**Amicus Therapeutics UK Operations Limited 2023 Methodological Note  
Disclosure of Payments and Transfers of Value (Collectively “TOVs”)  
Healthcare Professionals and Healthcare Organisations Paid in 2023.**

Amicus is proud to work with healthcare professionals for the benefit of patients. These interactions allow Amicus to gather advice and insights on a wide range of topics including medicines development, patient treatment pathways, health economics and clinical best practice.

Amicus is committed to compliance with transparency laws that enable patients to understand if, and how much, funding their healthcare professionals have received from industry and for what purpose.

As a member of the Association of the British Pharmaceutical Industry (the “**ABPI**”), an EFPIA affiliated organization, Amicus Therapeutics UK Operations Limited (“**Amicus**”) is committed to ensuring that the nature and scope of TOVs paid to healthcare professionals (“**HCPs**”) and healthcare organizations (“**HCOs**”) are transparent to the public.

This Methodological Note provides information about how Amicus has recorded and publicly reported TOVs provided directly or indirectly to HCPs or HCOs in calendar year 2023, in accordance with the current edition of the ABPI Code of Practice for the Pharmaceutical Industry.

**Reporting period / Reportable TOVs**

The Amicus 2023 disclosure includes TOVs paid to healthcare professionals and healthcare organisations, between 1 January 2023 and 31 December 2023.

Payments to healthcare professionals and healthcare organisations made after 31 December 2023 will be disclosed in the 2024 report.

Cross border transactions have been included where appropriate.

**Data Privacy**

Where healthcare professionals were contracted and paid during 2023, Amicus has disclosed transfers of value on the basis of legitimate interests. Each time that a transfer of value is contemplated, an agreement is signed by Amicus and the relevant healthcare professional. In all cases, a privacy notice is attached to the agreement confirming Amicus’ intention to disclose transfers of data in accordance with the ABPI Code and the legal basis for doing so.

Prior to 2023, Amicus relied on consent as the legal basis for disclosure of TOVs. Therefore, where Amicus has paid TOVs during 2023, on the basis of contracts executed prior to 2023, Amicus relies on consent for the purpose of transparency.

**HCP/HCO Number of Recipients Reported At An Aggregate Level**

Each category of TOVs reported at an aggregate level includes the number of HCPs/HCOs provided with a TOV. Each HCP/HCO that received a TOV is counted as one recipient in each category. The total number of recipients may therefore include individual HCPs/HCOs that received one or more TOV during the reporting period.

Payments made to academic institutions have not been included in the Amicus disclosure.

### **Cross Border Interactions**

TOVs paid by Amicus affiliates to either: (i) a healthcare professional with the UK as his/her principal place of practice; or (ii) a healthcare organization registered in the UK, have been included in the Amicus disclosure.

### **VAT & Withholding Taxes**

Where applicable, disclosure of HCP and HCO payments do not include VAT.

Where applicable, for services provided in locations outside of United Kingdom, TOV amounts will be reported as set out in the agreement, subject to inclusion of travel costs as appropriate.

### **Currency**

All information is reported in GBP.

### **Exchange Rate**

Where TOVs were captured in foreign currency, amounts were converted to local currency based on monthly average rates.

### **Rounding**

For each HCP/HCO, TOVs for each reporting category are rounded to the nearest GBP amount. The total amount for each HCP/HCO represents the sum of the reporting category amounts.

The table below describes the type of activities that are included in each category in the Amicus disclosure:

| <b>Category</b>   | <b>Type of Activity.</b>   |
|---|--|
| HCP TOV<br><br>Educational/Scientific Events  | Fee for Service and Consultancy<br>Speaking fee (including associated preparation work)<br>Advisory Boards and other consultancy engagements (including associated preparation work)<br>Chairing a meeting<br>Training   |
| Related expenses agreed in the Fee for Service or consultancy contract, such as:                          | Flights<br>Hotel<br>Other transportations costs (mileage, train, taxi, bus, underground, parking)<br>Note: Where incidental expenses are immaterial and unable to be disaggregated from the fees, said expenses will be disclosed under the Fee for Service and Consultancy Fees category. |
| Contribution to cost of events e.g. sponsorship for registration fees, travel and accommodation, such as: | Congress/Meeting registration<br>Flights<br>Hotel  |

|  |   |
|--|---|
|  | Other transportations costs (mileage, train, taxi, bus, underground, parking)   |
| HCO TOV Definition   | <p>Fee for Service and Consultancy Services</p> <p>Speaking fee (including associated preparation work)</p> <p>Advisory Boards and other consultancy engagements (including associated preparation work)</p> <p>Chairing a meeting</p> <p>Training</p> <p>Educational/Scientific Events</p>   |
| Related expenses agreed in the Fee for Service or consultancy contract   | <p>Flights</p> <p>Hotel</p> <p>Other transportations costs (mileage, train, taxi, bus, underground, parking)</p>  |
| Contribution to cost of events   | <p>Congress/Meeting registration</p> <p>Flights</p> <p>Hotel</p> <p>Other transportations costs (mileage, train, taxi, bus, underground, parking)</p>   |
| Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an event, such as part funded independent education events. | <p>When sponsorship also included catering costs as part of a sponsorship package which included other forms of funding to enable the event to take place (e.g. logistical costs), then it was included as a TOV (sponsorship).</p> <p>Where indirect sponsorship of an HCP occurs through an HCO, the TOVs will be disclosed in the name of the HCO recipient.</p> <p>Where the Amicus sponsorship is provided through a conference organizer, the TOV will be disclosed in the name of the recipient HCO.</p> <p>Where a vendor is organizing an event (via Amicus provided sponsorship) on behalf of more than one HCO, then the TOVs will be disclosed in the name of each HCO recipient.</p> |
| Donations and Grants to HCOs and Benefits in Kind to HCOs  |   |
| Payments made to HCOs for collaborative working projects and Investigator initiated research   |   |

### **Date Methodology**

Amicus followed the date methodology below when determining which TOVs are in scope for the current reporting cycle:

- Event Date is defined as the date the expense occurred.

TOV related to the following categories will use the Event Date when determining applicability for current year reporting requirements (e.g., did the event occur within the reporting period 1 January 2023 to 31 December 2023):

- Fee for Service and Consultancy: Expenses
- Contribution to Cost of Events: Registration Fees
- Contribution to Cost of Events: Travel and Accommodation

Paid Date is defined as the date the payment was provided to the covered recipient.

TOVs related to the following categories use the Paid Date when determining applicability for current year reporting requirements (e.g., did the payment occur within the reporting period 1 January 2023 to 31 December 2022):

- Fee For Service and Consultancy: Fee
- Contribution to Cost of Events: Sponsorship Agreements
- Grants and Donations
- Research and Development

### **Multiyear Contracts**

For multiyear contracts, disclosure only includes TOVs applicable during the reporting period (1 January 2023 and 31 December 2023).

### **Research & Development**

For the purpose of disclosure, research and development TOVs are related to the planning or conduct of clinical trials and research. The total aggregate disclosure includes transfers of value made by Amicus to clinical trial sites in the UK.

Biological samples and investigational compounds will be excluded from R&D disclosures. These compounds are subject to provisions under the Clinical Trial Directive (their use is submitted in the clinical trial approval process).

The loan of laboratory equipment that is used exclusively for the purpose of a clinical study will not be disclosed in the R&D aggregate amount. The loan of equipment does not constitute a permanent benefit.

Enquiries relating to Amicus' disclosure should be addressed to [Disclosure-ABPI@amicusrx.com](mailto:Disclosure-ABPI@amicusrx.com).